Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11910291 | 0.88 | MAPT (0.46) | SLC1A5ACHEMAPTL3MBTL1RAB9A | |
| SCHEMBL13523564 | 0.85 | ACHE (0.48) | SLC1A5ACHEMAPTL3MBTL1HPGD | |
| SCHEMBL15158671 | 0.83 | ACHE (0.46) | ACHEMAPTL3MBTL1RAB9AATM | |
| SCHEMBL25875513 | 0.83 | MAPT (0.40) | ACHEMAPTL3MBTL1RAB9AATM | |
| SCHEMBL23239915 | 0.80 | PGK1 (0.41) | SLC1A5ACHEKMOGPR3PGK1 | |
| SCHEMBL2414604 | 0.80 | SLC1A5 (0.43) | SLC1A5L3MBTL1MEN1ALDH1A1MAPK1 | |
| SCHEMBL1105470 | 0.80 | ACHE (0.65) | ACHEMAPTL3MBTL1RAB9AHPGD | |
| SCHEMBL10196126 | 0.80 | ACHE (0.65) | ACHEMAPTL3MBTL1RAB9AHPGD | |
| SCHEMBL29855159 | 0.80 | SLC1A5 (0.43) | SLC1A5L3MBTL1MEN1ALDH1A1MAPK1 | |
| SCHEMBL8737272 | 0.79 | GPR3 (0.43) | ACHEHPGDCYP2C9ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129780-A1 | BENZIMIDAZOLE DERIVATIVES AS GPX4 INHIBITORS | SONATA THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20230271928-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271928-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-3733663-B1 | 1-[6-[[4-(PHENYLAMINO)-6-QUINAZOLINYL]OXY]-3-AZABICYCLO[3.1.1]HEPT-3-YL]-2-PROPEN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS IRREVERSIBLE INHIBITORS OF PAN-HER TYROSINE KINASE FOR THE TREATMENT OF CANCER | CHENGDU JINRUI FOUND BIOTECH CO LTD (CN) | 2023-05-17 | — | — | EP | disclosed |
| WO-2023017452-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-02-16 | — | — | WO | disclosed |
| EP-3686198-B1 | MU-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2022-12-14 | — | — | EP | disclosed |
| EP-3416962-B1 | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | SANOFI SA (FR) | 2021-05-05 | — | — | EP | disclosed |
| US-20210078958-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2021-03-18 | — | — | US | disclosed |
| EP-3733663-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | Medshine Discovery Inc. (CN) | 2020-11-04 | — | — | EP | disclosed |
| EP-3686198-A1 | mu-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2020-07-29 | — | — | EP | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-05-10 | — | — | US | disclosed |
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-05-10 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-0481317-B1 | Method for dechlorination and/or debromination of aromatic compounds containing fluorine with chlorine and/or bromine | BAYER AG (DE) | 1995-08-09 | — | — | EP | disclosed |
| US-5283378-A | Process for the dechlorination and/or debromination of fluorine-and chlorine- and/or bromine-containing aromatic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1994-02-01 | — | — | US | disclosed |
| EP-0481317-A2 | Method for dechlorination and/or debromination of aromatic compounds containing fluorine with chlorine and/or bromine | BAYER AG (DE) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078958-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | ABL1, ERBB2, FLT3 | SLC1A5 640/4885ACHE 1788/4885MAPT 2054/4885 |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | FLT4, FLT1, TIE1 | SLC1A5 431/4885ACHE 4845/4885MAPT 4537/4885 |
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | GCGR, GLP1R, GCG | SLC1A5 1945/4885ACHE 1331/4885MAPT 4636/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | SLC1A5 919/4885ACHE 956/4885MAPT 3082/4885 |
| US-20230271928-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | C1R, C9, H1-3 | SLC1A5 2634/4885ACHE 1375/4885MAPT 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.